Relapsed/refractory multiple myeloma (RRMM): Best practices in treating early RRMM

$Relapsed/refractory multiple myeloma (RRMM): Best practices in treating early RRMM$

Relapsed/refractory multiple myeloma (RRMM): The relevance of adding a new MoAПодробнее

$Relapsed/refractory multiple myeloma (RRMM): The relevance of adding a new MoA$

Relapsed/refractory multiple myeloma (RRMM): Best practices in treating early RRMMПодробнее

$Relapsed/refractory multiple myeloma (RRMM): Best practices in treating early RRMM$

Optimising the management of multiple myeloma in the early relapsed/refractory settingПодробнее

$Optimising the management of multiple myeloma in the early relapsed/refractory setting$

Highlights- Optimising the management of multiple myeloma in the early relapsed refractory settingПодробнее

$Highlights- Optimising the management of multiple myeloma in the early relapsed refractory setting$

Hitting the BCMA Target in Multiple MyelomaПодробнее

Using novel therapeutic agents in early treatment for relapsed and refractory multiple myelomaПодробнее

$Using novel therapeutic agents in early treatment for relapsed and refractory multiple myeloma$

First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dex in pts with RRMMПодробнее

Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMMПодробнее